bleeding

Inexpensive generic prevents bleeding deaths after childbirthAn inexpensive generic drug has been found to prevent hemorrhaging in women after childbirth.
Xarelto reduces hospital stays: StudyHospital stays were shorter for patients treated with Xarelto (rivaroxaban) in a new study, compared to those receiving standard anticoagulants.
Bleeding disorder drug shows positive resultsAfter positive phase 3 trial data for its treatment for the bleeding disorder von Willebrand disease, Baxalta Inc. is awaiting FDA approval for the drug.
Rivaroxaban versus warfarin for NVAF patients scheduled for catheter ablation: New insightsNonvalvular atrial fibrillation (NVAF) patients taking uninterrupted rivaroxaban or warfarin had a low rate of major bleeding and thromboembolic complications, according to data presented at Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions, and published in the European Heart Journal.
FDA approves first spray-dried sealant to stop bleedingThe FDA approved Raplixa (fibrin sealant [human]), used to help control bleeding during surgery, on April 30.
Antiprogestin CDB-2914 promising for uterine fibroids (VIDEO)William Fredette, MD, discusses the benefits of Antiprogestin CDB-2914 for reducing uterine fibroid size and bleeding, and improving quality of life for affected women, as reported in the journal Fertility and Sterility. Video provided by The Doctor's Channel.
Study: Edoxaban safer alternative to warfarin for Afib patientsThe direct oral factor Xa inhibitor edoxaban was found to be noninferior to well-managed warfarin for preventing strokes or systemic embolism in patients with atrial fibrillation.
New molecular entityThe first nonactivated agent for the urgent reversal of vitamin K antagonist anticoagulation in adults with acute major bleeding
FDA approves drug for blood clotting disordersFDA approved a pooled plasma (human) blood product (Octaplas, Octapharma) for the replacement of clotting proteins (coagulation factors) in certain medical conditions where patients have insufficient levels.